Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: wherein A and B can be C or N and D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Abstract: Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

Abstract: Corticotropin releasing factor (CRF) antagonists of formula (I): ##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

Abstract: The present invention describes novel benzimidazoles of formula: ##STR1## or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Abstract: The present invention describes novel thiazolo[4,5-d]pyrimidines of formula: ##STR1## wherein R.sup.3 is a substituted aromatic or heteroaromatic group, or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Abstract: The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.

Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein *, A,B, n, R.sup.1, R.sup.2 and X are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are useful in selectively activating or inhibiting neurotransmitter release; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to activate or inhibit neurotransmitter release in mammals.

Abstract: Ethylene/(meth)acrylic acid copolymers which have improved melt-thermal stability are described. The copolymers contain an intrachain anhydride unit derived from an additional comonomer which is an anhydride or anhydride forming comonomer, such as maleic anhydride and maleic acid or its monomethyl ester, present at a level of 0.05 to 3.0 weight percent. Measured properties of the terpolymers, other than thermal stability, are about the same as comparable ethylene/(meth)acrylic acid copolymers with no anhydride monomer.

Abstract: New ethylene/acid copolymer ionomers which contain both (meth)acrylic acid and certain dicarboxylic acid monomers are described. The polymers may be melt processed as readily as ethylene/(meth)acrylic acid dipolymer ionomers, in contrast to ethylene/acid copolymer ionomers containing only dicarboxylic acid monomer derived in-chain acid units. Polymers with typical levels of (meth)acrylic acid and low levels of diacid provide ionomers comparable to existing ionomers, but which have adhesive and polymer blend compatibilizing characteristics, while polymers with higher levels of diacid will exhibit properties which depend on in-chain diacid derived units.

Abstract: Ethylene/carboxylic acid ionomers may be made, using a meltspun, and particularly meltblown process, into microfibers and thence to filter webs which are efficient gas filters for removing particles having a diameter of from 0.5 to 20 microns from a gas. The webs are effective without a deliberate specific post-charging operation during production. A deliberate post-charging operation can also be carried out to result in further efficiency.

Abstract: Ionomers based on ethylene/unsaturated carboxylic acid copolymers are modified with from 0.5 to 15 weight percent adipic acid. The modified-ionomers have improved melt flow and melt processing behavior over unmodified ionomers having a comparable level of neutralization of acid groups present. Certain mechanical properties are improved, particularly stiffness, abrasion resistance and low temperature izod impact.

Abstract: Ethylene/carboxylic acid ionomers may be made, using a meltspun, and particularly meltblown process, into microfibers and thence to filter webs which are efficient gas filters for removing particles having a diameter of from 0.5 to 20 microns from a gas. The webs are effective without a deliberate specific post-charging operation during production. A deliberate post-charging operation can also be carried out to result in further efficiency.

Abstract: This invention relates to a method of producing nucleophilic amine functionalized polyolefins by reacting a polymer carrying an electrophilic functional group with a diamine having amino end-groups having different reactivities. The nucleophilic amine functionalized polyolefin has the composition:Polyolefin-X--R.sub.1 --NHR.sub.2where X is selected from the group of imide, amide, sulphonamide or amineR.sub.1 is a bivalent organic radicalR.sub.2 is H or an alkyl groupThe nucleophilic amine functionalized polyolefin has uses as a compatibilizer, adhesive, dyeable material, and dyability improver.

Abstract: The present invention relates to bonding resins having excellent adhesion to polar polymers, particularly ionomers, acid copolymers and ethylene vinyl alcohol copolymer. These resins preferably contain: 1) an ethylene polymer or copolymer (ungrafted, grafted or partially grafted); 2) a grafted elastomer; and 3) optionally, an ethylene alpha olefin copolymer which is wholly or partially grafted. Preferred grafting comonomers include maleic anhydride and derivatives thereof.

Abstract: Ethylene/(meth)acrylic acid copolymers which have improved melt-thermal stability are described. The copolymers contain an intrachain anhydride unit derived from an additional comonomer which is an anhydride or anhydride forming comonomer, such as maleic anhydride and maleic acid or its monomethyl ester, present at a level of 0.05 to 3.0 weight percent. Measured properties of the terpolymers, other than thermal stability, are about the same as comparable ethylene/(meth)acrylic acid copolymers with no anhydride monomer.

Abstract: Compounds having the structure ##STR1## where m is an integer of from one to nine; n is an integer of from one to four; W is selected from substituted or unsubstituted quinolyl, benzothiazolyl, or quinoxalyl, X is selected from C.sub.1-6 alkylene, C.sub.2-6 alkenylene and C.sub.2-6 alkynylene; Y is selected from halogen, C.sub.1-6 alkyl and C.sub.1-6, alkoxy; and Z is selected from --C(O)B; --C(R.sub.2).sup.2 --O--N.dbd.A--C(O)B; and --C(R.sup.2).dbd.N--O--A--C(O)B where A is C.sub.1-6 alkylene and B is --OH, --O--M.sup.+, --OD where D is a metabolically cleavable group, --OR.sup.6 where R.sup.6 is hydrogen or C.sub.1-6 alkyl, --NR.sup.6 R.sup.7 where R.sup.7 is hydrogen, C.sub.1-6 alkyl, hydroxy or C.sub.1-6 alkoxy, or where R.sup.6 and R.sup.7 taken together form a five to eight membered ring optionally containing one heteroatom selected from nitrogen, oxygen or sulfur, are inhibitors of leukotriene biosynthesis.

Abstract: Compounds having the formula: ##STR1## or a pharmaceutically acceptable salt thereof wherein W and Y at each occurrence are the same and W is selected from the group consisting of optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; Y is selected from optionally substituted phenylene and optionally substituted ##STR2## wherein the alkylene portion is of one to six carbon atoms; A is selected from alkylene, alkenylene, cycloalkylene, and optionally substituted ##STR3## wherein the alkylene portion is of one to six carbon atoms; and M is selected from hydrogen, a pharmaceutically acceptable cation, a pharmaceutically acceptable, metabolically cleavable group, --OR.sup.3, and --NR.sup.4 R.sup.

Abstract: Compounds having the formula ##STR1## wherein W and Y are independently selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, and optionally substituted naphthyl with the proviso that W and Y are not simultaneously the same substituent; R.sup.1 and R.sup.2 are independently hydrogen, alkyl, haloalkyl, alkoxy, or halogen; R.sup.3 is hydrogen or alkyl; X is absent or is alkylene, alkenylene, or alkynylene; and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.4 wherein R.sup.4 is hydrogen or alkyl; and (c) --NR.sup.5 R.sup.6 wherein R.sup.5 and R.sup.6 are independently selected from hydrogen, alkyl, hydroxy and alkoxy are disclosed. These compounds inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states.